Back

prof. dr. E.E. Voest

prof. dr. E.E. Voest

Full Professor
prof. dr. E.E. Voest
  • Department of Medical Oncology

Research Programs

Strategic Program Cancer

Biography

Biography

Emile Voest is professor of Medical Oncology, senior group leader at the Netherlands Cancer Institute, senior scientist of the Oncode Institute, and translational scientist. He is the current chair of the board of directors of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. Until 2021, he served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation. He recently has co-founded Mosaic Therapeutics, devoted to developing new combinatorial treatments in a specific genomic background.

 

His academic group is devoted to bringing precision medicine to patients and is focused on large scale genomic sequencing of patients with metastatic cancer, the development of co-culture models of primary cultures of tumors (i.c. organoids) and immune cells to improve drug development and immunotherapy and to determine which treatment is best for a specific patient via computational, integrated approaches.

Side Activities

1999-   Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht (UP)

2010-   Chair of the Scientific Advisory Board of InteRNA (PtP)

2013-   Editorial board of Clinical Cancer Research (UP)

2015-   Editorial board of JAMA Oncology (UP)

2015-   Member of supervisory board Hartwig Medical Foundation (UP)

2016-   Editorial board ESMO Open, Cancer Horizons (UP)

2016-   Executive Board of Cancer Core Europe (UP)

2016-   Advisor Biogeneration Ventures (PtP)

2019-   Senior Group Leader of the Oncode Institute (UP)

2019-   Advisor of Agalia Venture Capital (UP)

2019-   Managing director, Executive Board of Directors, Cancer Core Europe (UP)

2020-2022   Advisor Frame Therapeutics (UP)

2021-   Scientific Advisory Committee (SAC) for Omico (trading as the Australian Genomic Cancer Medicine Centre (AGCMC) (UP)

2021-   Clinical Advisory Board Cambridge Cancer Center, UK (UP)

2021-   Scientific Advisory Board Institute Gustave Roussy, Paris, France (PtP)

2021-   Scientific Advisory Board GROW Oncology, Maastricht, Netherlands (UP)

2022-   Independent, non-executive board member Sanofi, Paris, France (PtP)

2022-   Co-founder Mosaic Therapeutics, Cambridge, UK (PtP)

2022-   Board member Center for Personalized Cancer Treatment (UP)

UP=unpaid
PtP= paid to person

Research Output (284)

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

van Berge Henegouwen J M, Jebbink M, Hoes L R, van der Wijngaart H, Zeverijn L J, van der Velden D L, Roepman P, de Leng W W J, Jansen A M L, van Werkhoven E, van der Noort V, van der Wekken A J, de Langen A J, Voest E E, Verheul H M W, Smit E F, Gelderblom H 15 Jun 2022, In: European Journal of Cancer. 171 , p. 114-123 10 p.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

Kester Lennart, Seinstra Danielle, van Rossum Annelot G.J., Vennin Claire, Hoogstraat Marlous, van der Velden Daphne, Opdam Mark, van Werkhoven Erik, Hahn Kerstin, Nederlof Iris, Lips Ester H., Mandjes Ingrid A.M., van Leeuwen-Stok A. Elise, Canisius Sander, van Tinteren Harm, Imholz Alex L.T., Portielje Johanneke E.A., Bos Monique E.M.M., Bakker Sandra D., Rutgers Emiel J., Horlings Hugo M., Wesseling Jelle, Voest Emile E., Wessels Lodewyk F.A., Kok Marleen, Oosterkamp Hendrika M., van Oudenaarden Alexander, Linn Sabine C., van Rheenen Jacco 1 Mar 2022, In: Clinical Cancer Research. 28 , p. 960-971 12 p.

Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from Genomics - Guided Treatment

Hoes Louisa R, van Berge Henegouwen Jade M, van der Wijngaart Hanneke, Zeverijn Laurien J, van der Velden Daphne L, van de Haar Joris, Roepman Paul, de Leng Wendy J, Jansen Anne M L, van Werkhoven Erik, van der Noort Vincent, Huitema Alwin D R, Gort Eelke H, de Groot Jan Willem B, Kerver Emile D, de Groot Derk Jan, Erdkamp Frans, Beerepoot Laurens V, Hendriks Mathijs P, Smit Egbert F, van der Graaf Winette T A, van Herpen Carla M L, Labots Mariette, Hoeben Ann, Morreau Hans, Lolkema Martijn P, Cuppen Edwin, Gelderblom Hans J, Verheul Henk M W, Voest Emile E 19 Jan 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28 , p. 1402-1411 10 p.

Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types

van der Wijngaart Hanneke, Hoes Louisa R, van Berge Henegouwen J Maxime, van der Velden Daphne L, Zeverijn Laurien J, Roepman Paul, van Werkhoven Erik, de Leng Wendy W J, Jansen Anne M L, Mehra Niven, Robbrecht Debbie G J, Labots Mariette, de Groot Derk Jan A, Hoeben Ann, Hamberg Paul, Gelderblom Hans, Voest Emile E, Verheul Henk M W 2 Sep 2021, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 27 , p. 6106-6114 9 p.

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

Ooft S. N., Weeber F., Schipper L., Dijkstra K. K., McLean C. M., Kaing S., van de Haar J., Prevoo W., van Werkhoven E., Snaebjornsson P., Hoes L. R., Chalabi M., van der Velden D., van Leerdam M., Boot H., Grootscholten C., Huitema A. D.R., Bloemendal H. J., Cuppen E., Voest E. E. 19 Apr 2021, In: ESMO open. 6 , p. 100103 1 p.

Study protocol:Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)

Samsom Kris G, Bosch Linda J W, Schipper Luuk J, Roepman Paul, de Bruijn Ewart, Hoes Louisa R, Riethorst Immy, Schoenmaker Lieke, van der Kolk Lizet E, Retèl Valesca P, Frederix Geert W J, Buffart Tineke E, van der Hoeven Jacobus J M, Voest Emile E, Cuppen Edwin, Monkhorst Kim, Meijer Gerrit A Dec 2020, In: BMC Medical Genomics [E]. 13 , p. 1-7

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

Dijkstra Krijn K, Monkhorst Kim, Schipper Luuk J, Hartemink Koen J, Smit Egbert F, Kaing Sovann, de Groot Rosa, Wolkers Monika C, Clevers Hans, Cuppen Edwin, Voest Emile E 5 May 2020, In: Cell Reports. 31 12 p.

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer

Bijlsma Rhode, Wouters Roel, Wessels Hester, Sleijfer Stefan, Beerepoot Laurens, Ten Bokkel Huinink Daan, Cruijsen Hester, Heijns Joan, Lolkema Martijn P, Steeghs Neeltje, van Voorthuizen Theo, Vulink Annelie, Witteveen Els, Ausems Margreet, Bredenoord Annelien, May Anne M, Voest Emile Apr 2020, In: ESMO open. 5 9 p.

Tumor organoid–T-cell coculture systems

Cattaneo Chiara M., Dijkstra Krijn K., Fanchi Lorenzo F., Kelderman Sander, Kaing Sovann, van Rooij Nienke, van den Brink Stieneke, Schumacher Ton N., Voest Emile E. 1 Jan 2020, In: Nature Protocols. 15 , p. 15-39 25 p.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

van Dessel Lisanne F., van Riet Job, Smits Minke, Zhu Yanyun, Hamberg Paul, van der Heijden Michiel S., Bergman Andries M., van Oort Inge M., de Wit Ronald, Voest Emile E., Steeghs Neeltje, Yamaguchi Takafumi N., Livingstone Julie, Boutros Paul C., Martens John W. M., Sleijfer Stefan, Cuppen Edwin, Zwart Wilbert, van de Werken Harmen J. G., Mehra Niven, Lolkema Martijn P. 1 Dec 2019, In: Nature Communications. 10

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet